A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2022-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo,
in participants with moderate-to-severe atopic dermatitis (AD).